High Tower Advisors, LLC Chemo Centryx, Inc. Transaction History

High Tower Advisors, LLC

$68.3 Billion
Q3 2024

Shares

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 09, 2022	BUY	$22.17 - $51.8 $155,943 - $364,361	7,034 New	7,034 $364,000
Q2 2022 Aug 10, 2022	SELL	$15.36 - $27.51 $202,152 - $362,059	-13,161 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$22.22 - $39.12 $129,653 - $228,265	5,835 Added 79.65%	13,161 $334,000
Q4 2021 Feb 10, 2022	BUY	$18.38 - $40.5 $134,651 - $296,703	7,326 New	7,326 $266,000
Q3 2021 Nov 12, 2021	SELL	$13.18 - $19.83 $138,693 - $208,671	-10,523 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$9.59 - $50.88 $33,392 - $177,164	3,482 Added 49.45%	10,523 $141,000
Q1 2021 May 10, 2021	SELL	$49.53 - $68.4 $89,154 - $123,120	-1,800 Reduced 20.36%	7,041 $361,000
Q4 2020 Feb 10, 2021	BUY	$47.25 - $65.16 $1,937 - $2,671	41 Added 0.47%	8,841 $547,000
Q1 2020 May 21, 2020	SELL	$32.73 - $50.78 $2,454 - $3,808	-75 Reduced 0.85%	8,800 $354,000
Q4 2019 Feb 14, 2020	BUY	$6.81 - $39.55 $60,438 - $351,006	8,875 New	8,875 $351,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.